Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: mesalabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $120.00 | Underweight | Wells Fargo |
| 1/4/2024 | $100.00 → $125.00 | In-line → Outperform | Evercore ISI |
LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter ("2Q25") ended September 30, 2024 (amounts in thousands). Second quarter FY 2025 compared to second quarter FY 2024: Revenues increased 8.8%Non-GAAP core organic revenues¹ decline was 2.8%Operating income increased 5,947% to $3,508 Non-GAAP adjusted operating income excluding unusual items² increased 18.9% and was 24.8% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Cl
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter ("1Q25") ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024: Revenues increased 14.9%Non-GAAP core organic revenues1 growth was 3.0%Operating income increased 940%Non-GAAP adjusted operating income excluding unusual items2 increased 47.0% and was 26.4% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Clinical Genomics ("
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q24") and fiscal year ("FY24") ended March 31, 2024 (amounts in thousands). Fourth quarter FY24 compared to fourth quarter FY23: Revenues increased 6% and increased 10.2% vs 3Q24Non-GAAP core organic revenues1 decreased 3.5%Operating (loss) was $(271,284) which included a $274,533 non-cash impairment chargeNon-GAAP adjusted operating income excluding unusual items2 increased 26.3% and was 25.4% as a percentage of revenues Full
Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced the closing of its Amended and Restated Credit Agreement (the "Credit Agreement"), which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A. The Credit Agreement includes a $75 million senior secured term loan facility (the "Term Loan") and a $125 million senior secured revolving credit facility (the "Revolver"), both of which mature in April 2029. The Credit Agreement includes a ten-year amortization schedule and no springing maturity relating to the Company's 1.375% Convertible Senior
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
LAKEWOOD, Colo., April 01, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 24, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. For more
LAKEWOOD, Colo, March 15, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB, "Mesa" "we" "our" or the "Company"))), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced the release of its second annual Environmental, Social and Governance ("ESG") Program Brochure. Rooted in Mesa's unwavering commitment to Protecting the Vulnerable®, this brochure highlights the Company's continued strides in environmental stewardship, social responsibility, and corporate governance. The latest edition of Mesa's ESG Program Brochure is marked by two updates from the past fiscal year, signifying a new chapter in the Company's
LAKEWOOD, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q24") ended December 31, 2023. Third quarter FY 2024 compared to third quarter FY 2023: Revenues decreased 1.5% but increased 0.6% vs 2Q24Non-GAAP core organic revenues3 decreased 9%Operating income decreased 102% Non-GAAP adjusted operating income1 excluding unusual items decreased 6.8% but increased 7.3% vs 2Q24 Non-GAAP adjusted operating income excluding unusual items as a percentage of revenues increased sequentially to 22.4% Execut
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us", or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the "Board"), effective January 5, 2024. Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: "We are pleased to welcome Mark to Mesa's Board. Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics. We believe Mark's insights will be pivotal to Mesa
LAKEWOOD, Colo., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or the "Company") today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors ("Board"), effective November 3, 2022. Mr. Ladiwala assumes this newly re-created role as an expansion of his current responsibilities on the Board, on which he has served since October 2021. Mr. Ladiwala was selected for this important role due to the thoughtful leadership and contributions he has made to the Board as well as the exceptional breadth of his professional experience. Mr. Ladiwala said, "I am delighted to accept this leadership role on Mes
LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the "Board"), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr. Tripeny's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. Mr. Tripeny is likely to be appointed to the Audit Committee and brings extensive financial experience to the Board. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent
LAKEWOOD, Colo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021. Shiraz previously worked in leadership roles at Thermo Fisher Scientific and retired on August 31, 2021. With Mr. Ladiwala's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. "Shiraz's extensive experience building a world class life sciences company and his knowledge in corporate development and the Asia/ Pacific region will be instrumental to helping Mesa achieve its strategic objectives" said John Sullivan, Ph.D
LAKEWOOD, Colo., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa Labs” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2021, to shareholders of record at the close of business on February 26, 2021. About Mesa Laboratories, Inc.Mesa Labs is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, medical device, industrial safety, environmental, and food and beverage industries. Mesa Labs offers products and services through four divisions (St
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
DEF 14A - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
NT 10-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00
Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
Evercore ISI Group analyst Vijay Kumar maintains Mesa Laboratories (NASDAQ:MLAB) with a Outperform and lowers the price target from $120 to $106.
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
The postponement is due to the ongoing year-end audit, which is finalizing calculations and technical accounting for previously announced impairments of long-lived assets and goodwill in the Clinical Genomics and Biopharmaceutical Development divisions, as well as the purchase accounting for the acquisition of GKE. Mesa's Form 10-K filing deadline with the SEC is June 14, 2024.
Mesa's Form 10-K will be filed the same day. The earnings announcement has been delayed as it finalizes the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to Clinical Genomics and Biopharmaceutical Development divisions. Mesa's Form 10-K filing deadline with the SEC is June 14, 2024.
Evercore ISI Group analyst Vijay Kumar maintains Mesa Laboratories (NASDAQ:MLAB) with a Outperform and raises the price target from $124 to $130.
Mesa Laboratories (NASDAQ:MLAB) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $0.19 by 963.16 percent. This is a 14.04 percent decrease over earnings of $2.35 per share from the same period last year. The company reported quarterly sales of $53.47 million which missed the analyst consensus estimate of $54.89 million by 2.59 percent. This is a 1.50 percent decrease over sales of $54.29 million the same period last year.
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million. • Affiliated Managers Group (NYSE:AMG) is projected to report quarterly earnings at $5.98 per share on revenue of $524.15 million. • Sphere Entertainment (NYSE:SPHR) is expected to report quarterly loss at $0.85 per share on revenue of $300.23 million. • Bowlero (NYSE:BOWL) is estimated to report quarterly earnings at $0.12 per share on revenue of $300.52 million. • ON Semiconductor (NASDAQ:ON) is estimated to report quarterly earnings at $1.21 per share on revenue of $2.00 billion. • Tyson Foods (NYSE:TSN) is likely to repo
Mesa Laboratories (NASDAQ:MLAB) is set to give its latest quarterly earnings report on Monday, 2024-02-05. Here's what investors need to know before the announcement. Analysts estimate that Mesa Laboratories will report an earnings per share (EPS) of $0.19. Mesa Laboratories bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $1.76, which was followed by a 1.53% in
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
LAKEWOOD, Colo. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product
Lakewood, Colo., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us" or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the completed acquisition of GKE-GmbH's sterilization indicators business and its accredited, independent testing lab SAL GmbH. Additionally, Mesa has entered into a definitive agreement to purchase GKE's Chinese sales entity, Beijing GKE Science & Technology Co. LTD ("GKE China"). The total purchase price for the acquisition of the three entities is €85M (of which €5M is associated with GKE China), which is subject to customary purchase price adj
LAKEWOOD, Colo., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, i
LAKEWOOD, Colo., July 05, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integ
LAKEWOOD, Colo., April 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2023, to shareholders of record at the close of business on May 31, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase
LAKEWOOD, Colo., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, incr
Lakewood, Colorado, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("we", "Mesa" or the "Company"), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the acquisition of substantially all of the assets (other than current assets) and certain liabilities related to Belyntic GmbH's ("Belyntic") peptide purification business. The transaction price and near-term financial impact are not material to Mesa's ongoing operations. "The acquisition of Belyntic's peptide purification products provide Mesa with a natural complement to our peptide syn